WebApr 2, 2024 · Presenting author Jonathan Cunningham, MD, of Brigham & Women’s Hospital, and colleagues sought to assess the relationship between NT-proBNP and HFpEF patient outcomes, and the relative effect of sacubitril/valsartan as observed in the Novartis-sponsored PARAGON-HF. The original trial reported results showing the combination … WebFeb 16, 2024 · This label expansion is based on efficacy and safety evidence observed in PARAGON-HF, the largest and only Phase III active-controlled study to date in patients with guideline-defined HFpEF 2,5,6. The greatest benefit was shown in patients with LVEF below normal 6. Approximately 6 million Americans are living with chronic heart failure (CHF) 4.
The Effect of Angiotensin Receptor-Neprilysin Inhibition on …
WebSep 1, 2024 · PARAGON-HF was designed to test the hypothesis that sacubitril/valsartan would improve outcomes in HFpEF. A total of 4,822 patients were randomly assigned to … WebMar 30, 2024 · The PARAGON-HF trial failed to show that sacubitril/valsartan reduced adverse events among patients with HFpEF. Description: The goal of the trial was to … philip budinger ipswich
Efficacy and Safety of LCZ696 Compared to Valsartan, on …
WebMethods: The PARAGON-HF trial is a randomized, double-blind, parallel group, active-controlled, event-driven trial comparing the long-term efficacy and safety of valsartan and sacubitril/valsartan in patients with chronic HFpEF (left ventricular ejection fraction ≥45%), New York Heart Association functional class II to IV symptoms, elevated ... WebAug 29, 2024 · The PARAGON-HF and EMPEROR-Preserved trials were designed to recruit similar groups of patients. Both trials required patients to have symptoms of heart failure … WebOct 22, 2024 · The PARAGON-HF trial found that Angiotensin Receptor-Neprilysin Inhibition (ARNI) has potential benefits for the management of HFpEF. Nevertheless, the role of ARNI in cardiac fibrosis in HFpEF are still unclear. We will conduct a prospective randomized controlled trial to evaluate the effect of ARNI on cardiac fibrosis in patients with HFpEF ... philip buckley md moses lake